Published in Drug Week, May 14th, 2004
The clinical study is designed to determine the safety and tolerability of APF530, and will include approximately 18 healthy volunteers at a single clinical site in the United Kingdom. The company expects to complete this study by mid-year. A.P. Pharma is also finalizing preclinical work prior to filing an Investigational New Drug (IND) application in the U.S. that could allow the company to go directly into U.S. phase II studies in cancer patients with APF530 later in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.